Updated 2 days ago
Last progress June 27, 2025 (7 months ago)
Last progress June 5, 2025 (8 months ago)
Introduced on June 5, 2025 by Bill Cassidy
Expands Medicare coverage for intensive behavioral therapy (IBT) for obesity by allowing more kinds of clinicians and a community counseling program to furnish and be paid for IBT, subject to coordination and referral rules. It also changes Medicare Part D language to improve coverage of obesity medications (with the Part D change taking effect for plan years starting at least two years after enactment) and requires HHS to report to Congress within one year and every two years on implementation and coordination across federal programs. The bill aims to increase access to obesity treatment for adults on Medicare, adjust prescription coverage rules for anti-obesity drugs, and create ongoing federal reporting and recommendations to improve clinical care and program coordination.
About 41 percent of adults aged 60 and over had obesity in 2015–2016, representing more than 27,000,000 people.
The National Institutes of Health reported that obesity and overweight are the second leading cause of death nationally, with an estimated 300,000 deaths a year attributed to the epidemic.
Obesity increases the risk for chronic diseases and conditions, including high blood pressure, heart disease, certain cancers, arthritis, mental illness, lipid disorders, sleep apnea, and type 2 diabetes.
More than half of Medicare beneficiaries are treated for 5 or more chronic conditions per year; the rate of obesity among Medicare beneficiaries doubled from 1987 to 2002 and nearly doubled again by 2016. Medicare spending on individuals with obesity rose proportionately to reach $50,000,000,000 in 2014.
Men and women with obesity at age 65 have decreased life expectancy: 1.6 years less for men and 1.4 years less for women.
Who is affected and how:
Medicare beneficiaries (especially older adults with obesity): Gain potential new access to intensive behavioral therapy from a broader set of clinicians and from an added community counseling program. Over time, expanded access could improve weight-related outcomes and reduce complications of obesity, but beneficiaries may face variable access depending on geographic provider availability and whether new providers enroll in Medicare.
Health care providers and community counseling programs: New provider types and community programs can become eligible to furnish and bill Medicare for IBT if they meet the law’s coordination, referral, location, and privacy conditions. This creates new revenue opportunities but also administrative work to comply with Medicare enrollment, billing, and clinical coordination requirements.
Medicare Part D plan sponsors and pharmacy benefit administrators: Must prepare to modify formularies, coverage policies, and utilization management for obesity medications after the statutory change becomes effective (plan years beginning two years after enactment). Plans will need to balance access, utilization management, and cost control.
Department of Health and Human Services and CMS: Responsible for issuing implementing guidance (eligibility, billing, privacy/location standards), overseeing provider and program enrollment, and producing the required reports to Congress. HHS will also need to coordinate across federal programs that support obesity research, prevention, and clinical care.
Federal budget and long‑term care systems: Increased utilization of IBT and obesity pharmacotherapy may raise Medicare outlays in the near term. Potential downstream savings from reduced incidence or severity of diabetes, cardiovascular disease, and other obesity-related conditions could offset costs over time, but those savings are uncertain and dependent on treatment effectiveness and sustained weight loss.
Implementation and operational considerations:
Net effect summary: The bill broadens access pathways for obesity treatment under Medicare and adjusts Part D coverage rules, creating opportunities for improved clinical care but requiring administrative action from CMS, plans, and providers and producing uncertain net fiscal effects depending on uptake and long‑term outcomes.
Read twice and referred to the Committee on Finance.
